Skip to content

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080225337
Enrollment
500
Registered
2020-08-24
Start date
2020-09-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : spesolimab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investiga

Sponsors

None listed

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
safety

Secondary

MeasureTime frame
efficacy

Countries

Europe, Japan, North America, Oceania

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026